-
Mashup Score: 4
Mid-November 2024 | ASH Clinical News | American Society of Hematology Mid-November 2024 Developments and Discoveries With advances in hematology emerging daily, the 2024 ASH Annual Meeting and Exposition offers hematologists the chance to stay on the cutting edge. Viewpoints Editor’s Corner Peer Review and the Yellow Brick Road Education Hematologica Obscura Hematologists Should Consider Sitosterolemia in Patients with Hemolytic…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. An analysis of treatment-naïve patients with acute myeloid leukemia (AML) receiving venetoclax plus azacitidine demonstrates that the European LeukemiaNet (ELN) AML genetic risk classification systems do not provide clinically meaningful stratification of overall survival (OS) for patients who are ineligible for intensive chemotherapy. The authors of the study, which was published in Blood, also provide a four-gene
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
A new genetics-based risk model aims to predict survival outcomes for patients with #AML treated with #venetoclax and #azacitidine. By analyzing genetic mutations, the model may stratify OS outcomes more accurately than the ELN risk classifications: https://t.co/JsJI4EXdgr
-
-
Mashup Score: 1
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Currently, the standard of care for the management of smoldering multiple myeloma (SMM) is observation. However, ear ly treatment of patients with high-risk (HR) SMM resulted in high rates of sustained undetectable measurable residual disease (uMRD) at the end of treatment, according to a trial published in the Journal of Clinical Oncology. 1 “The role of early treatment in SMM is a topic of ongoing debate. While research is still in
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Early, aggressive treatment of high-risk #SmolderingMultipleMyeloma led to high rates of sustained uMRD, according to recent research. This early intervention could delay progression, challenging the traditional "watch and wait" approach: https://t.co/OUwkMEEwGx https://t.co/Go4QGfB5Dw
-
-
Mashup Score: 0
Kenneth A. Bauer, MD Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School A 39-year-old female has a history of bilateral pulmonary embolism (PE) after taking oral contraceptive pills (OCPs), as well as a subsequent deep vein thrombosis (DVT) in the left calf after a long car ride. Given the recurrent event and her history of venous thromboembolism (VTE), would you treat with indefinite anticoagulation? For both provoked and unprovoked below-the-knee DVT, I typically treat
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Check out what our expert had to say in this month's edition of You Make the Call! https://t.co/dOoDcPUoqm
-
-
Mashup Score: 2FDA Approves Hemophilia A, B Treatment | ASH Clinical News | American Society of Hematology - 10 day(s) ago
Marstacimab-hncq was approved by the U.S. Food and Drug Administration (FDA) as a prophylactic treatment for bleeding episodes in patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. The treatment is an anti-tissue factor pathway inhibitor that works by reducing the amount of anticoagulation protein and increasing the amount of thrombin. It is a subcutaneous, once-weekly treatment. Approval was granted based on the results of an open-label,
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Marstacimab-hncq was approved by the #FDA as prophylaxis for #bleeding episodes in patients with #hemophilia A and B after studies demonstrated it significantly reduced annualized bleeding rates compared with routine prophylaxis and on-demand treatment: https://t.co/3DSvqvCsT6
-
-
Mashup Score: 0Bluebird Bio Medication Linked to Blood Cancers | ASH Clinical News | American Society of Hematology - 14 day(s) ago
Seven of 67 pediatric patients receiving Bluebird Bio’s elivaldogene autotemcel (eli-cel) for the treatment of cerebral adrenoleukodystrophy developed a blood cancer, according to a study published in the New England Journal of Medicine (NEJM). Of the patients who developed a hematologic malignancy, six were diagnosed with myelodysplastic syndromes (MDS) and one with acute myeloid leukemia (AML). These hematologic malignancies occurred at 14, 2 6, 28, 36, 42, 57, and 92 months after receiving eli-cel
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Seven out of 67 #pediatric patients who were receiving elivaldogene autotemcel for the treatment of #cerebral #adrenoleukodystrophy were reported to have developed a #blood #cancer, with diagnoses ranging from 14 to 92 months after treatment: https://t.co/Ioh0CqZPTU
-
-
Mashup Score: 3
November 2024 | ASH Clinical News | American Society of Hematology November 2024 When Treatment Includes Substance Use Disorders A patient’s substance use disorder can complicate treatment for a hematologic condition, but physicians must view the comorbidity as an opportunity to provide support. Viewpoints Editor’s Corner Bridging the Divide: Global Equity in CAR T-Cell Therapy Education You Make the Call…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The November issue is available now! Highlights include a feature on treating substance use disorders in patients with #hematologic diseases, findings on #ischemic #stroke rates in individuals with #SCD, and more. View the full issue here: https://t.co/3vxiEffAQ8 https://t.co/zoqkcmTmu9
-
-
Mashup Score: 0Fixed-Duration Regimen Safe, Effective for CLL | ASH Clinical News | American Society of Hematology - 21 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Patients with previously untreated chronic lymphocytic leukemia (CLL) who receive one-year fixed-duration treatment with venetoclax-obinutuzumab (Ven-Obi) experience sustained long-term survival, undetectable measurable residual disease (uMRD), and quality-of-life (QoL) benefits. Othman Al-Sawaf, MD, a hematologist at the University Hospital of Cologne in Germany, and colleagues published the six-year results of the randomized
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
One-year fixed-duration treatment with #venetoclax and #obinutuzumab led to sustained long-term survival, undetectable measurable residual disease, and quality-of-life benefits for patients with previously untreated #ChronicLymphocyticLeukemia: https://t.co/hQvevvIwGZ
-
-
Mashup Score: 1
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Treatment with teclistamab in patients with relapsed or refractory multiple myeloma (R/R MM) who had been previously treated with an anti-B-cell maturation antigen (BCMA) treatment resulted in statistically significant and clinically meaningful responses to the antibody. The overall response rate (ORR) in the clinical trial was 52.5%, and 30.0% of patients achieved a complete response (CR) or better. The median
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
In patients with R/R #MultipleMyeloma and prior #BCMA therapy, treatment with #teclistamab resulted in statistically significant and clinically meaningful responses, with a 52.5% ORR and a CR or better in 30% of patients: https://t.co/5ygrrSNVH2
-
-
Mashup Score: 3Prognostic Factors and Treatment Outcome in Mycosis Fungoides and Sezary Syndrome | ASH Clinical News | American Society of Hematology - 24 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. A long-term retrospective study by Zhuo-Fan Xu, MD, of the Chinese Academy of Medical Science in Beijing, and colleagues has revealed new factors that predict prognosis and can help in treatment selection for patients with advanced mycosis fungoides (MF) and Sezary syndrome (SS). The results, published in Hematology, confirm that patients with MF/SS experience a wide range of survival and risk of progression. The authors thus
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Recent findings from researchers in China confirm that patients with advanced #MycosisFungoides and #SezarySyndrome experience a wide range of survival and progression risk, with recommendations for the use of disease-specific risk-stratification methods: https://t.co/sNfvAwk3pe
-
See what's to come at #ASH24 in this month's bonus issue! Special highlights include interviews with the Education and Scientific program co-chairs and previews of sessions on #aging, #endoflife care, and treatment of smoldering #myeloma 🩸 https://t.co/hxop5ClUpB https://t.co/fyUjTqxTps